An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
Recruiting · NCT06238401 · Registry updated 2025-11-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 | 2025-11-24 | NCT06238401 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hangzhou Adcoris Biopharmacy Co., Ltd | 2 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Tumor Hospital | Beijing | China | 1 |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing | China | 71 |
| Shandong First Medical University affiliated Cancer Hospital of Shandong | Shandong | China | 1 |
| Shanghai Chest Hospital | Shanghai | China | 83 |
| Shanghai sixth people's hospital | Shanghai | China | 31 |
| Zhejiang Cancer Hospital | Zhejiang | China | 2 |